KRAS and adenocarcinoma: Consistent with patient data [110], Kras mutations are identified as an early event, Cdkn2a can be epigenetically downregulated in early foci and later deleted in both adenomas and adenocarcinomas, while Trp53 mutations are found in adenocarcinomas but not hyperplasias, supporting a role for Trp53 in invasion [60].